Ekulizumab
(Preusmjereno sa stranice Eculizumab)
| Klinički podaci | |
|---|---|
| Robne marke | Soliris, Soliris (Alexion Pharmaceuticals) |
| AHFS/Drugs.com | Monografija |
| Identifikatori | |
| CAS broj | 219685-50-4 |
| ATC kod | nije dodeljen |
| DrugBank | DB01257 |
| ChEMBL[1] | CHEMBL1201828 
|
| Hemijski podaci | |
| Formula | ? |
| Mol. masa | 148 kDa |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 82 h |
| Farmakoinformacioni podaci | |
| Trudnoća | ? |
| Pravni status | |
| Način primene | Intravenozno |
Ekulizumab (INN i USAN; prodajno ime Soliris) jeste humanizovano monoklonalno antitelo. Ono je prvo u klasi terminalnih inhibitora komplementa, kao i prva terapija koja je odobrena za lečenje paroksizmalne noćne hemoglobinurije (PNH), retke, progresivne, i u pojedinim slučajevima smrtonosne bolesti karakterisane prekomernim uništavanjem crvenih krvnih zrnaca (hemolizom).[2][3][4][5][6][7][8]
Reference[uredi | uredi kod]
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.
- ↑ Hillmen, Young, Schubert, P, N, J, et al (2006). „The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria”. N Engl J Med 355 (12): 1233–1243. DOI:10.1056/NEJMMoa061648. PMID 16990386.
- ↑ Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, Roth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L: The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006 Sep 21;355(12):1233-43. PMID 16990386
- ↑ Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, Nye SH, Matis LA, Squinto SP, Evans MJ: Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol. 1996 Dec;33(17-18):1389-401. PMID 9171898
- ↑ Dmytrijuk A, Robie-Suh K, Cohen MH, Rieves D, Weiss K, Pazdur R: FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist. 2008 Sep;13(9):993-1000. Epub 2008 Sep 10. PMID 18784156
- ↑ Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L: Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007 Nov;25(11):1256-64. PMID 17989688
- ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682.
- ↑ David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412.
Literatura[uredi | uredi kod]
- Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7.
- Thomas L. Lemke, David A. Williams, ur. (2007). Foye's Principles of Medicinal Chemistry (6 izd.). Baltimore: Lippincott Willams & Wilkins. ISBN 0-7817-6879-9.
